TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Contrast-induced nephropathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of bronchopulmonary dysplasia (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extended activities of daily living scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Readmissions over 12 months
Endpoint domain: Resource use
Primary endpoint: Satisfaction with EDC compared to QNN
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived usefulness and ease of use of EDC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum plasma concentration (C(max)) of duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the plasma concentration‐time curve (AUC) of duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Minor postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Low-Density Lipoprotein Cholesterol (LDL-cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variance of systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Log[high-sensitive C-reactive protein (hs-CRP)] levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rectal hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain threshold (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of unsatisfactory smears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with serum cholesterol concentrations measured
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Analgesic intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: first-phase insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise-induced ST segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cycling endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pAKT expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: dentin loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure-related rehospitalization rates
Endpoint domain: Mortality/survival
Primary endpoint: use of antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: need for adenoidectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum level of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knowledge gain about sleep
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of suicidality detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F1 score of suicidality detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of recovery from depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until recovery from depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in astigmatic vector power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Protein Malnutrition prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: initial hospitalization for heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Haemodynamic profile stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median half-life for gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of diaphragmatic paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of forced expiratory volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: High fecal HBD2 levels at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: High fecal HNP1‐3 levels at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: QTcmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tpeak-Tend intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parasite clearance time (PCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fever subsidence time (FST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coma resolution time (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance on 60-m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CMJ (Countermovement Jump)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dissatisfaction with patient safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Negative effect of duty hours on health and well-being outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dissatisfaction with resident education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time to response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum growth hormone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum testosterone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Stone Fragmentation Rate (SFR1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid peroxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probing pocket depths (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma controlled days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tissue Integrity (TI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of US and CT findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of US and CT findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of US and CT findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of antiallergic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sCD40L concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average pain score
Endpoint domain: Adverse events/effects
Primary endpoint: lower fentanyl consumption during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lower morphine consumption between the 4-12th postoperative hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lower pain intensity assessed according to VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxic side effects (myelosuppression and gastrointestinal reaction)
Endpoint domain: Adverse events/effects
Primary endpoint: Rise of T-lymphocyte subgroup and NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: C-terminal telopeptide crosslinks levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: night time serum PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Achieving recommended serum theophylline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to gastrostomy tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exertional increase in global constructive work (GCW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Homeostasis model assessment of insulin resistance (HOMA‐IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impaired functional performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of individuals who improved (with at least one symptom alleviated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of people reporting no symptoms or 'cured'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact scores between the two groups
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Readability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of contents
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ocular discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: respiratory discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: skin discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Retention rates at 1 and 3 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attendance at outpatient program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C(max) for rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC₀₋(∞) for rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary blood cell velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Loss of ERBHAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dp-uc-MGP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in active melanocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of degeneration in melanocytes and keratinocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Coronary Artery Calcium Score (CACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: All-cause mortality at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in LV mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PCNA‐MPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total score of social cognition
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: negative subjective score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in GSM symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Impact on sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: motor-milestone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance visual acuity of both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupillary size under bright light in the left eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: near point of convergence break
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic MOR mRNA and protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enterocyte STAT3-phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success of teeth restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of stool free periods >72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: score for emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: morphine equivalent opioid doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPT response to Ara h 2 and Ara h 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean placebo-corrected intra-subject reduction in MABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: National Institutes of Health (NIH) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pinch acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in parent-adolescent relationships
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heart Rate Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of dysphagia complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myopic shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-Time Product (PTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory flow response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intelligibility improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUC of venlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUC of desvenlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: R-wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient compliance with remote monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transmission success rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recurrent hyperparathyroidism (HPT) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Permanent hypoparathyroidism rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for second operation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of radical surgeries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reliability of smRSq
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to administer smRSq
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in BLS from low altitude baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: palpation of the vocal tract structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceptual voice assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: singing range obtained from acoustic analysis of glissando
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average accumulated QALYs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete endoscopic duct clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in stone size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lp(a) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HOMA-IR index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in demineralization of enamel blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration of ionic composition of dental biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of upper gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean serum retinol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of low serum retinol (< 20 micrograms/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pulmonary artery catheter-related bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in number of concomitant pain treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients not using pain drugs after 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to donate biospecimens
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Donating for the benefit of future generations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consultation and Relational Empathy (CARE) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: amylopsin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decisional capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reticulated platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduced activation in the left inferior frontal gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: enhanced functional connectivity between the left IFG and subcortical structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decreased functional connectivity following CBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite primary outcome (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death)
Endpoint domain: Mortality/survival
Primary endpoint: Adverse reactions to food
Endpoint domain: Adverse events/effects
Primary endpoint: risk of a heavy drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of wave P2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative atrial fibrillation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall incidence of postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean caries experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in level of sexual energy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative bleeding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes